The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tolerability of raltitrexed when it is used in monotherapy and in combination with oxaliplatin (TOMOX) as advanced colorectal cancer treatment in normal clinical practice.
Manuel Constenla
No relevant relationships to disclose
Jorge Aparicio
No relevant relationships to disclose
M.Auxiliadora Gomez
No relevant relationships to disclose
Cristina Gravalos Castro
No relevant relationships to disclose
Miriam Lopez-Gomez
No relevant relationships to disclose
Jose Luis Manzano
No relevant relationships to disclose
Maria Dolores Pineda
No relevant relationships to disclose
Juana Maria Cano
No relevant relationships to disclose
Isabel Sevilla
No relevant relationships to disclose
Jose Maria Vieitez de Prado
No relevant relationships to disclose
Antonio Viudez
No relevant relationships to disclose
Luis Lopez-Gomez
No relevant relationships to disclose
Juan Carlos Camara
No relevant relationships to disclose
Guillermo Lopez-Vivanco
No relevant relationships to disclose
Fuensanta Aranda
No relevant relationships to disclose
Paloma Isabel Palomo-Jimenez
Employment or Leadership Position - Hospira
Ana Barbon
Employment or Leadership Position - Hospira
Jaime Feliu Batlle
No relevant relationships to disclose